Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression

LINDSAY C. DAVIES,a,b NINA HELDRING,a,b NADIR KADRI,a,c KATARINA LE BLANC,a,b

Key Words. Adult human bone marrow • Adult stem cells • Cytokines • Marrow stromal stem cells • T cells • Immunomodulation • Programmed-death 1

INTRODUCTION

Mesenchymal stromal cells (MSCs) have been extensively reported to possess immunosuppressive properties via the modulation of immune cells within both the innate and adaptive systems [1–4]. Their mode of action is differential, with a plethora of soluble factors as well as contact-dependent mechanisms documented to influence their ultimate effect on immune cell function.

Delineating the mechanism of action and cell signaling pathways involved in mediating MSC immunomodulation is of critical importance as these cells become a therapeutic option for the treatment of various immunological disorders, such as Graft versus Host Disease (GvHD), diabetes, and amyotrophic lateral sclerosis (ALS) [5–7].

It is well documented that MSCs can both directly and indirectly alter the status of CD4+ T cells, suppressing their proliferation and skewing them toward a regulatory phenotype (Treg) [8, 9]. MSCs require licensing to an anti-inflammatory phenotype, via exposure to pro-inflammatory cytokines, upregulates cell surface and secreted forms of both ligands. Blocking experiments confirm their role in suppressing T cell proliferation, interleukin-2 secretion, inducing hyporesponsiveness and cell death. Suppressed T cells demonstrated a reduction in AKT phosphorylation at T308 and a subsequent increase in FOXO3 expression that could be reversed with blockade of PD-L1. In conclusion, we demonstrate for the first time, that MSCs express and secrete PD-L1 and PD-L2 and that this is regulated by exposure to interferon γ and tumor necrosis factor α. MSCs, via their secretion of PD-1 ligands, suppress the activation of CD4+ T cells, downregulate interleukin-2 secretion and induce irreversible hyporesponsiveness and cell death. Suppressed T cells demonstrated a reduction in AKT phosphorylation at T308 and a subsequent increase in FOXO3 expression that could be reversed with blockade of PD-L1. In conclusion, we demonstrate for the first time, that MSCs are able to secrete PD-1 ligands, with this being the first known report of a biological role for PD-L2 in MSCs. These soluble factors play an important role in modulating immunosuppressive effects of MSCs directly on T cell behavior and induction of peripheral tolerance.
convey their immunomodulatory effects. Interferon γ (IFN-γ) is well reported to license MSCs, with its removal significantly reducing the anti-proliferative effects on T cells [10]. Tumor necrosis factor α (TNFα) is additionally an important T cell effector cytokine in MSC immunomodulation. Its effects are differential to that of IFNγ, with known roles in modulating heme-oxygenase 1 (HO-1) and insulin-like growth factor 1 (IGF-1) [11].

Complete activation of T cells requires a complex cascade of intracellular signaling events initiated through the T cell receptor (TCR) and enhanced by costimulatory signals such as CD28. These positive signals drive cellular metabolism, inhibit cell death and enhance proliferation [12]. The receptor programmed death-1 (PD-1) is expressed on the cell surface of activated T and B cells, in addition to myeloid cells and thymocytes [13]. Interaction of PD-1 with its known ligands, PD-L1/B7-H1 and PD-L2/B7-DC provides an inhibitory signal in regulating cellular activation and proliferation [14–16]. The importance of the PD-1 pathway in T cell homeostasis is evident, with PD-1 knockout mice demonstrating splenomegaly and an increased susceptibility to autoimmune diseases [17, 18]. Awareness and understanding of the importance of the PD-1 pathway and its regulation is increasing, with reports suggesting a pivotal role in mouse models of GvHD [19] and inflammatory responses, suggesting that within fibroblasts this is not a mechanism of T cell suppression [20]. Further investigations into the potential interplay of MSCs with this pathway are essential in establishing mechanisms of action for MSC therapy.

PD-L1 is reported to be expressed on both non-hematopoietic (including MSCs) and some subsets of hematopoietic cells [21–23]. In contrast, PD-L2 has a more restricted expression profile to activated antigen presenting cells (APCs), with a few reports suggesting cell surface expression on MSCs [21, 22, 24]. Whilst the amino acid identity between PD-L1 and PD-L2 is approximately 40%, the affinity of PD-L2/PD-1 binding is reportedly two to six fold higher than that of PD-L1/PD-1. Therefore, it is expected that PD-L2, if expressed at the same level as PD-L1, would outcompete its rival. However, in general, PD-L2 is expressed at much lower levels than PD-L1 [25].

Soluble (s)PD-1 ligands arise from the proteolytic cleavage of the membrane bound form of the protein and, in the case of sPD-L2, the transcription of splice variants [26, 27]. No splice variants have been detected to date for PD-L1, but specific cleavage by matrix metalloproteinase (MMP) 13 to the soluble form has been described in foreskin fibroblasts [26]. Cell surface cleavage of PD-L2 has been reported to be less specific, with sensitivity to both MMP 9 and 13. Two splice variants of human PD-L2 have also been reported, with variant III created by splicing out of exon 3, resulting in loss of the transmembrane domain [27]. Conversion to the soluble form in foreskin fibroblasts has been linked to loss of immunosuppressive activity and exacerbation of inflammatory responses, suggesting that within fibroblasts this is not a mechanism of T cell suppression [26].

Previous studies have demonstrated a role for MSC inhibition of T cell proliferation and effector function via contact-dependent interactions of PD-1/PD-L1 with IFNγ licensing [21, 28]. However, little is understood about the mechanism of MSC interactions with the PD-1 pathway and ultimately how this interplay affects downstream signaling cascades and T cell function. To the authors’ knowledge, no study has reported the secretion of sPD-1 ligands by human MSCs and whether these ligands can directly affect activated T cells. The aim of this study was therefore to elucidate whether MSCs, in addition to their contact-dependent effects, can produce sPD-1 ligands and the mechanism by which these soluble factors can suppress T cell proliferation and effector function.

### MATERIALS AND METHODS

#### Isolation and Expansion of MSCs

Bone marrow (BM) MSCs (n = 5 donors) were isolated, expanded, and characterized as described previously [6, 29, 30] in line with the guidelines of the MSC Consortium of the European Blood and Marrow Transplantation Group and approved by the Swedish National Board of Health and Welfare [6, 31]. The study was approved by the review board at Karolinska University Hospital, Huddinge with donors providing informed written consent in line with the Helsinki declaration.

To isolate MSCs, BM mononuclear cells were separated over a gradient of Percoll (Redigrad, GE Healthcare, Uppsala, Sweden), washed and resuspended in DMEM low-glucose medium (Invitrogen, Stockholm, Sweden) supplemented with 5% pooled human platelet rich plasma and 100 IU/ml penicillin, 0.1 mg/ml streptomycin and 0.25 µg/ml Fungizone (Invitrogen; herein termed as culture media) and plated at a density of 1.6 × 10⁵ cells/cm². When the cultures reached confluence (>80%), the cells were detached with 0.05% Trypsin-EDTA (Invitrogen), replated at a density of 4 × 10³ cells/cm² and cultured for up to five passages.

#### Co-Culture of MSCs and Purified T Cells

Peripheral blood mononuclear cells were prepared by centrifugation of heparinized blood on Ficoll-Isopaque (Lymphoprep, Oslo, Norway) and untouched CD3+ T cells were isolated by magnetic activated cell sorting (MACS; Human Pan T Cell Isolation Kit; Miltenyi Biotec Norden AB, Lund, Sweden). T cells were activated using anti-CD2/CD3/CD28 microbeads (Miltenyi Biotec) at a 1:2 bead to cell ratio and cultured in RPMI 1640 medium supplemented with penicillin (100 U/ml), streptomycin (0.1 mg/ml), L-glutamine (2 mM; Invitrogen) and 10% heat-inactivated pooled human blood type AB serum (herein termed T cell media). MSCs (Passage 2 [P2]; n = 5 donors) were added at a 1:10 ratio to T cells either in direct contact or in 0.4 µm PET transwell membrane inserts and cultured for 3 days. Where relevant anti-PD-L1 (250 ng/ml polyclonal goat anti-human PD-L1, #AF156; R&D Systems, Abingdon, U.K. [32]), anti-PD-L2 (250 ng/ml polyclonal goat anti-human PD-L2, #AF1224; R&D Systems) or anti-PD-1 (50 ng/ml monoclonal mouse anti-human PD-1, #329911; Biolegend, San Diego, CA) were added to co-cultures.

#### Evaluating the Hyporesponsive State of T Cells Induced by MSCs

T cells from the above transwell co-cultures were counted and transferred to 96-well plates (1 × 10⁵ cells/well in triplicate) in fresh T cell media ± fresh activation microbeads. Where appropriate 15 ng/ml interleukin-2 (IL-2; Peprotech Nordic, Stockholm, Sweden) was added to cultures to evaluate potential for reverting to a responsive state. Cells were cultured at 37°C/5%CO₂ for 3 days before the addition of 5Ci/mM³H thymidine. Cultures were maintained for a further 16
hours at 37°C before harvesting. Cells were harvested onto a glass fiber filter (Harvester 96, Tomtec Inc., Hamden, CT) and radioactivity quantified using a micro-β scintillation counter (Perkinelmer Sverige AB, Upplands Vasby, Sweden).

**Flow Cytometry Analysis for Surface and Phosphorylated Molecules**

**MSC Cell Surface Expression of PD-L1 and PD-L2.** MSCs (P2; n = 4 donors) were cultured in culture media ± 100 IU/ml IFNγ and/or 10 ng/ml TNFα for 3 days before trypsinizing and staining with anti-PD-L1 PE (#12-5983) or anti-PD-L2 APC (#17-5888) as per the manufacturer’s instructions (eBioscience Inc., San Diego, CA). Cells were acquired on a FACSCalibur (BD Biosciences, Stockholm, Sweden).

**T Cell Expression Profile After MSC Co-Culture.** T cells were stained with anti-CD3 V450 (#560365; BD), anti-CD4 PerCP-Cy5.5 (#560650; BD), anti-CD25 PE (#555432; BD) and anti-PD-1 eVolve655 (#86-2799; eBioscience) and run on a BD LSRFortessa (BD).

**T Cell Viability.** For the assessment of T cell survival, cells were stained with 5 μl of 7-AAD (BD) and 5 μl of annexin V (Av) PE (#640907; Biologend) in Av binding buffer (0.1 M HEPES [pH 7.4], 1.4 M NaCl, and 25 mM CaCl2). Cells were acquired on a FACSCalibur (BD).

**Phospho-AKT Detection.** After 3 days of transwell co-culture, T cells were isolated and restimulated with plate-bound anti-CD3 (2 μg/ml; BD) for 10 minutes in a water bath at 37°C. The stimulation was attenuated by fixation with BD cytofixation buffer (BD) for 10 minutes at 37°C. Cells were then permeabilized with Perm Buffer III (BD) for 30 minutes on ice before staining with anti-p-AKT (pT308) antibody (#562465; BD) for 1 hour. For intracellular FOXO3 staining, cells were fixed using fixation buffer (eBioscience) for 30 minutes. Cells were washed twice before permeabilizing with permeabilizing buffer (eBioscience) for 30 minutes at room temperature. Permeabilized cells were treated with anti-FOXO3 (#2497; Cell Signaling Technology Europe BV, Leiden, The Netherlands) for 20 minutes, followed by 20 μg/ml goat anti-rabbit Alexa Fluor 647 secondary antibody (#4414; Cell Signaling Technology) for 20 minutes. Cells were washed twice with FACS buffer before acquiring on a BD LSRFortessa (BD).

Fifty thousand gated events were recorded per sample and analyzed using FlowJo Version 7.6 (FlowJo, Ashland, OH).

**Enzyme-Linked Immunosorbent Assay (ELISA)**

MSCs (n = 5 donors) were stimulated with 100 IU/ml IFNγ and/or 10 ng/ml TNFα for 3 days. Secretion of sPD-L1 and sPD-L2 was measured using ELISA as per the manufacturer’s instructions (R&D Systems). For sPD-L1 measurement, conditioned media samples were concentrated approximately 2.5-fold (degree of concentration measured for individual samples) using 10K cut-off Amicon Ultra centrifugal filters (Millipore AB, Solna, Sweden).

Suppression of T cell effector function was assessed by measurement of TNFα, IL-2, and IFNγ within the co-culture supernatants by ELISA as per the manufacturer’s instructions (R&D Systems).

**Gene Expression Analysis Using Real-Time Quantitative PCR**

Total RNA was extracted from MSCs ± IFNγ and/or TNFα stimulation (n = 4 donors) and T cells post-transwell culture (n = 4 donors) using the RNeasy Mini Kit (QIAGEN AB, Sollentuna, Sweden). cDNA was synthesized using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Stockholm, Sweden) and qRT-PCR was performed with Fast SYBR Green Master Mix (Applied Biosystems). The amplification was performed on a CFX384 C1000 Touch Real-time system (Bio-Rad Laboratories AB, Sundbyberg, Sweden). Expression was normalized to β-actin levels. The primers used were: β-actin; FW: AGCTCAGGCTGCTGAC, REV: AAGGTTTTCTGGTGGATGC; PD-L1; FW: GGACATCCAGATAAAGACTCAA, REV: CAGAAGTTCAGACTGGAAT, PD-L2; FW: GAGCTGTGGCAAGTCCTCAT, REV: GCAATTCCAGGCTCAACATTA; AKT; FW: GGCATTGGTGAAAGGAGGTTG, REV: TCTCTTGTACCAGAATGGTGTG. PD-L2 primers detect total PD-L2, including the splice variant III form.

**Statistics**

Comparisons were statistically analyzed using Student’s t test or Mann–Whitney U test where data did not fulfill requirements for parametric testing (normal distribution and equal variances). Significance was assumed at p < 0.05 (Prism 5.0; Graphpad Software Inc., La Jolla, CA and SPSS Statistics 24.0; IBM, Armonk, NY).

**Results**

**MSCs Constitutively Express and Secrete PD-1 Ligands**

MSCs were cultured ± the pro-inflammatory T cell effector cytokines and known MSC licensing factors, IFNγ and/or TNFα. MSCs were subsequently assessed for PD-L1 and PD-L2 expression at mRNA, cell surface and secreted levels. Our results demonstrate that MSCs constitutively express both PD-L1 and PD-L2 on their cell surface, although the effect was higher on PD-L2, with an 8-fold upregulation compared to controls (Fig. 1A; p < 0.01). A synergistic effect of IFNγ and TNFα inducing a 5.5-fold upregulation of PD-L1 (Fig. 1A; p < 0.05) but not PD-L2 (Fig. 1B) at the cell surface. These findings were also supported at the transcriptional level (Fig. 1C, 1D). Here the secretion of MSCs includes both free and vesicle bound proteins. Furthermore, we report differential responses to IFNγ and TNFα, with IFNγ inducing a 5.5-fold upregulation of PD-L1 (Fig. 1A; p < 0.05) but not PD-L2 (Fig. 1B) at the cell surface. These data are supported by a significant upregulation in mRNA levels of PD-L1, confirming response at the transcriptional level (Fig. 1E; p < 0.05). In contrast, TNFα induced an upregulation of both PD-L1 and PD-L2 on their cell surface (Fig. 1A, 1B) and actively secrete these immunomodulatory molecules (Fig. 1C, 1D). Here the secretion of MSCs includes both free and vesicle bound proteins. Furthermore, we report differential responses to IFNγ and TNFα, with IFNγ inducing a 5.5-fold upregulation of PD-L1 (Fig. 1A; p < 0.05) but not PD-L2 (Fig. 1B) at the cell surface. These data are supported by a significant upregulation in mRNA levels of PD-L1, confirming response at the transcriptional level (Fig. 1E; p < 0.05). In contrast, TNFα induced an upregulation of both PD-L1 and PD-L2 on their cell surface (Fig. 1A, 1B; p < 0.05 in 1A and p < 0.01 in 1B) at the cell surface, although the effect was higher on PD-L2, with expression increasing 3.4-fold compared to resting controls. These findings were also supported at the transcriptional level (Fig. 1F; p < 0.05). A synergistic effect of IFNγ and TNFα when used in combination, was evident on PD-L1 cell surface expression, resulting in a 5.6-fold increase over controls (Fig. 1A; p < 0.01) and a further 2.4-fold increase over TNFα stimulation alone (Fig. 1A; p < 0.01).

Effects of pro-inflammatory stimuli on the secreted levels did not map to the previously described modulation of cell surface expression. PD-L1 secretion was specifically upregulated in response to IFNγ and TNFα in combination (Fig. 1C; p < 0.05), whereas PD-L2 secretion levels increased in response to both cytokines, 4-fold by IFNγ and 3.3-fold by TNFα compared to
controls (Fig. 1D; \( p < .05 \)). It is noteworthy to comment that sPD-L2 levels were markedly higher than sPD-L1 in resting MSCs, with further dramatic upregulation upon licensing.

**MSCs Suppress T Cell Activation via the Secretion of PD-1 Ligands**

MSCs in direct contact or transwell co-culture with T cells suppressed T cell activation (CD25+) and PD-1 expression to a comparable level (Fig. 2Aii; \( p < .05 \)). Further experiments to delineate the mechanism of the PD-1 pathway in MSC-mediated immunosuppression were therefore performed in transwell cocultures. Addition of an anti-PD-1 blocking antibody to the MSC/T cell transwell co-culture reversed the inhibition of CD25 expression within CD4+ T cells back to that of controls (Fig. 2B; \( p < .05 \)). A partial reversal of CD25 inhibition was seen where each of the PD-1 ligands were blocked.
separately, suggesting a combinatory effect in down-regulating CD25 expression by the MSCs. In contrast down-regulation of PD-1 expression by the MSCs in CD4+ T cells could only be significantly restored by blockade of sPD-L2 (Fig. 2C; \( p < .05 \)), although blocking sPD-L1 demonstrated a trend toward a similar effect.

**MSCs Suppress IL-2 Secretion Through Soluble PD-1 Ligands**

Transwell co-culture of MSCs with T cells directly suppressed the secretion of IFN\( \gamma \) (Fig. 3A; \( p < .05 \)), TNF\( \alpha \) (Fig. 3B; \( p < .05 \)), and IL-2 (Fig. 3C; \( p < .05 \)). Blockade of the individual PD ligands did not reverse the suppression of IFN\( \gamma \) or TNF\( \alpha \) by the MSCs (Fig. 3A, 3B). However, both neutralization of sPD-L1 and sPD-L2 significantly restored the secretion of IL-2 by the activated T cells compared to MSCs alone (Fig. 3C; \( p < .01 \)).

**MSCs Induce Tolerance Through the Induction of T Cell Hyporesponsiveness and Apoptosis**

MSCs were cultured in transwell with activated T cells ± PD-1 blocker, before removal of the MSCs and their conditioned media. The primed T cells were then cultured with fresh media and activation stimuli ± IL-2 to assess whether the secretion of PD-1 ligands by the MSCs could suppress T cell proliferation and induce a hyporesponsive state.

As expected, exposure of the T cells to the PD-1 blocker in combination with the activation stimuli induced proliferation compared to the activated T cells alone (Fig. 4A; \( p < .01 \)).
Exposure to the MSC secretome induced a suppression of proliferation in the T cells that could not be reversed with removal of the conditioned media (containing MSC derived immunomodulatory soluble factors) and addition of fresh stimuli (Fig. 4A; \( p < .01 \)). Further supplementation of IL-2 did not reverse this suppressive effect, suggesting the T cells had been rendered unresponsive (Fig. 4A). The presence of the PD-1 blocker during co-culture of the MSCs/T cells prevented this phenomenon, allowing the T cells to proliferate once more in response to new activation stimuli (Fig. 4A; \( p < .01 \)).

Flow cytometry confirmed this lack of responsiveness was accompanied by a suppressed ability for the T cells to upregulate their cell surface CD25 and PD-1 expression in response to fresh stimulus and removal of the MSCs (Fig. 4B; \( p < .01 \)). Further supplementation with IL-2 did not alter this response (Fig. 4B; \( p < .001 \)).

T cell survival after MSC exposure was assessed by Av staining in combination with 7-AAD. Levels of apoptotic (Av + 7-AAD +) T cells were reduced with blocking of the PD-1 receptor and specifically sPD-L1 compared to MSCs alone (Fig. 4C; \( p < .01 \)). Total T cell death (7-AAD +) was increased with exposure to the MSC secretome compared to T cell only controls (Fig. 4C; \( p < .05 \)). This could be prevented by blocking of PD-1 or sPD-L1 to a similar extent, confirming the specific induction of T cell death via MSC secretion of sPD-L1 (Fig. 4C; \( p < .01 \)). Blocking of PD-L2 had no effect on levels of T cell death (7-AAD +) compared to MSCs alone.

**T Cell Hyporesponsiveness is Induced by MSCs Through PD-1-Mediated Blockade of the AKT Pathway**

To ascertain the intracellular mediated mechanisms of T cell behavior affected by exposure to MSC secreted soluble factors, the expression of AKT and downstream targets was investigated. RT-PCR of the T cells after co-culture with MSCs confirmed no change in mRNA expression of AKT (Fig. 5A). Phospho-flow was therefore utilized to confirm whether the phosphorylation status of signaling molecules downstream of the PD-1 receptor had been altered in response to MSC exposure. T cells previously co-cultured with MSCs in transwell were restimulated with CD3 after removal of the MSCs and their conditioned media. Prior exposure to MSCs induced a hyporesponsive state, suppressing the ability of the T cells to respond to CD3 stimulation, with a reduced phosphorylation of AKT at T308 (Fig. 5B; \( p < .05 \)) and a consequent upregulation of the AKT regulated transcription factor FOXO3 (Fig. 5C; \( p < .05 \)), but not FOXO1 (data not shown). Blockade of sPD-L1 secreted by the MSCs was able to partially restore levels of AKT phosphorylation (Fig. 5B; \( p < .05 \)) and completely suppress the FOXO3 upregulation seen (Fig. 5C; \( p < .05 \)), back to that of control levels.

**DISCUSSION**

The immunosuppressive qualities of MSCs have long been appreciated and studied [29, 33]. Multiple mechanisms of action have been proposed, both through contact-dependent induction of suppression and the release of soluble factors such as indoleamine 2,3-dioxygenase (IDO), prostaglandin E2, and HO-1 [9, 34]. As cellular therapy with MSCs becomes an accepted therapeutic option, focus has shifted toward delineating the intricate mechanisms of action by which MSCs mediate their effects on individual immune cell subsets.

Within this study we report, for the first time, the secretion of both sPD-L1 and sPD-L2 by BMMSCs. The previous report of PD-L1 within the microvesicles of murine MSCs suggests that these ligands may exist as free entities and/or vesicle bound within the MSC secretome [35]. As previously published, exposure to pro-inflammatory cytokines resulted in...
upregulation of both these ligands on the MSC cell surface [21, 36], but we also report that this induction extends to their secreted levels. Furthermore, we demonstrate the differential effects of IFNγ and TNFα, with the former upregulating cell surface expression of PD-L1 but not PD-L2. In contrast, TNFα upregulated both ligands at the cell surface. PD-L2 has a 2-6-fold higher affinity for the PD-1 receptor than PD-L1, but its low expression in comparison to APCs has led to the opinion that PD-L1 is the more important ligand in vivo [25]. Here we report that MSCs secrete significantly higher levels of sPD-L2 compared to sPD-L1 in both unstimulated/resting and licensed MSCs, indicating the potential importance of sPD-L2 in MSC immunomodulation.

Upregulation of cell surface PD-L1 on MSCs and subsequent inhibition of T cell proliferation via a contact-dependent mechanism has been previously reported [36–38]. In contrast, English et al. [39] reported that PD-L1 played no role in MSC-mediated immunosuppression. The differences in these reports have been attributed to the use of different immune cell subsets and species variation. Therefore, this study was designed to specifically investigate the effects of human BMMSCs on purified human CD3+ T cells.

Here we demonstrate that cell surface levels of PD-1 on T cells are dramatically upregulated in response to activation via CD3/CD28 costimulation. In order for MSCs to initiate inhibitory effects via the PD-1 pathway, they require T cells to be

**Figure 4.** MSCs induce hyporesponsiveness and apoptosis in T cells via their secretome. MSCs (n = 4) were co-cultured in transwell with activated T cells for 3 days. T cells were subsequently separated from the transwell MSC co-cultures and placed in fresh culture media and restimulated with anti-CD3, anti-CD2 and anti-CD28 microbeads. (A): T cell proliferation was significantly inhibited in those cells previously exposed to MSCs and could not be restored by IL-2 supplementation, indicative of irreversible hyporesponsiveness. Presence of a PD-1 blocker at the point of initial MSC/T cell co-culture prevented induction of this hyporesponsive state, with T cells proliferating to levels comparable to controls. Data are expressed as counts per minute ± SEM **, p < .01 (B): Flow cytometry (n = 5 MSC donors) confirmed the proliferation data, demonstrating a reduced ability for T cells to upregulate CD25 and PD-1 in response to fresh stimulus (± IL-2) after MSC exposure. Data are expressed as percentage CD4+CD25+PD-1+ T cells ± SEM **, p < .01; ***, p < .001 (C): Annexin V and 7-AAD staining of T cells post-MSC co-culture confirmed induction of apoptosis by exposure to the MSC secretome. Cells are defined as pre-apoptotic (Av-7-AAD-), apoptotic (Av-7-AAD+) or total dead cells (7-AAD+). Data are expressed as a percentage compared to T cell only controls ± SEM. Dotted line indicates 100%. #, p < .05 compared to T cell only control *; p < .05 **, p < .01 compared to T cells + MSC. Abbreviations: IFNγ, interferon γ; IL-2, interleukin-2; MSC, mesenchymal stromal cell; PD-1, programmed death-1; PD-L1 and PD-L2, programmed death 1 ligands 1 and 2; TNFα, tumor necrosis factor α.
expressing PD-1 on their cell surface (data not shown). MSCs can subsequently suppress the level of activated CD25+PD-1+ T cells both in direct contact and in transwell to the same extent. In contrast to the published literature, stating the need for direct cell contact for triggering of the PD-1 pathway, this suppression in T cell activation occurs directly through the interaction of sPD-1 ligands, secreted by MSCs, with blockade of the PD-1 receptor abolishing this effect. Neutralising the individual PD-1 ligands demonstrated a trend toward restoring CD25 expression in T cells suppressed by MSCs alone, but this was not statistically significant, indicating that both sPD-L1 and sPD-L2 play a combinatory role in exerting the suppression of T cell activation. In contrast, blockade of sPD-L2 alone was sufficient to prevent downregulation of PD-1 on the cell surface of the T cells, supporting its superior ability to bind to PD-1 compared to PD-L1. This shift in activation status may also represent a skewing toward a more regulatory phenotype. Francisco et al. [15] proposed that PD-L1 activation of the PD-1 pathway was sufficient for conversion of naive CD4+ T cells into FoxP3+ inducible Tregs to induce peripheral tolerance, a mechanism, which has already been reported for MSCs [9]. Further studies to delineate the effects of sPD-1 ligands on skewing of the immune cell repertoire would be needed to validate this hypothesis.

Effector cytokine analysis confirmed that exposure to the MSC secretome directly suppresses the production of IFNy, TNFα, and IL-2 in activated T cells, but that only IL-2 suppression can be attributed to sPD-1 ligand secretion by the MSCs. Blocking experiments confirmed that this suppressive effect is through both sPD-L1 and sPD-L2. These data support the above findings, that both sPD-L1 and sPD-L2 work in unison to exert their effects on activated T cells. In contrast to

Figure 5. MSC-mediated induction of the PD-1 pathway results in reduced AKT phosphorylation and increased FOXO3 expression in T cells. (A): T cells co-cultured with MSCs (n = 4) in transwell conditions were assessed for mRNA expression of the PD-1 pathway downstream signaling molecule AKT by qRT-PCR. No change in the transcriptional level of AKT in response to exposure to MSCs was evident. Data are expressed as fold change compared to activated T cell controls. (B): Phospho-flow confirmed that prior exposure of the T cells to MSCs renders the cells unable to respond to T cell receptor (TCR) stimulation with plate bound CD3, with a decrease in AKT phosphorylation at position T308. This ultimately increased the expression of transcription factor (C) FOXO3 within the MSC exposed T cells. MFI was used to quantify changes in expression between treatment groups. Bar charts indicate percentage change in MFI compared to T cell only controls ± SEM. *, p < 0.05. Abbreviations: MSC, mesenchymal stromal cell; MFI, mean fluorescence Intensity; PD-L1 and PD-L2, programmed death 1 ligands 1 and 2.
Chinnadurai et al. [21], we demonstrate that MSCs can disrupt IL-2 cytokine secretion via a contact-independent mechanism through the PD-1 pathway. Differential results could be potentially attributed to the different methods of detection. Secreted levels were detected here, in contrast to intracellular IL-2 levels, perhaps indicating a blockade in secretion but not intracellular accumulation of the cytokine. However, in agreement with Chinnadurai et al. [21], we report evidence for multiple suppressive pathways for MSCs, acting in both contact and contact-independent pathways through the PD-1 receptor on activated T cells, as well as other non-redundant mechanisms such as IDO. These findings demonstrate the importance of the multiple immunosuppressive pathways that MSCs exert, with each mode of action contributing to the complete overall effect observed.

It has previously been demonstrated that the downregulation of IL-2 via the PD-1 pathway is linked to T cell anergy [40, 41]. Here we demonstrate that, in addition to blocking the activation and effector function of T cells, MSCs can suppress T cell proliferation and induce irreversible hyporesponsiveness through sPD-1 ligands. This anergic state was not responsive to IL-2 supplementation. Furthermore, blockade of the PD-1 receptor completely prevented both suppression of proliferation and anergy. Anergic responses to MSCs have been previously reported within the literature [42]. This reported divisional arrest, purely suppressed T cell proliferation however and cells remained responsive through an upregulation of CD25 upon stimulation. In contrast, we demonstrate that the anergic response induced by MSCs through the PD-1 pathway affects both proliferation and response to stimulation via activation. Flow cytometry for CD25 and PD-1 confirmed that prior MSC exposure significantly suppressed T cell activation upon restimulation.

This induction of peripheral tolerance through anergy appears to be further supported by a second mechanism acting through T cell death. Av and 7-AAD staining of the cells established that a significant proportion of T cells die following exposure to the MSC secretome. Blocking of MSC secreted sPD-L1 could prevent this effect, whereas sPD-L2 had no effect on inducing T cell death. Induction of apoptosis in T cells has been established as a key mechanism in inducing peripheral tolerance through triggering transforming growth factor beta in macrophages and directly upregulating Treg induction [43].

It is well established that CD3/CD28 costimulation leads to tyrosine phosphorylation of CD28, recruiting and activating phosphoinositide 3-kinase (PI3K) [44]. The lipid products of PI3K bind proteins such as AKT. The AKT pathway has been directly linked to regulation of the FOXO family of transcription factors, mediating numerous cellular processes such as proliferation, apoptosis and cytokine production [45]. Of this family, FOXO3 has been shown to be central to inflammatory processes, with global deletion resulting in organ inflammation and dysregulation of T cell activation and proliferation.
Using phosho-flow, we demonstrate that binding of MSC secreted sPD-L1 to the PD-1 receptor results in a decrease in AKT phosphorylation. This inhibitory effect leads to a downstream upregulation of FOXO3 expression. This effect on FOXO3 can be reversed back to control levels with the addition of a PD-L1 blocker. As envisaged, blockade of PD-L1 only partially restored AKT phosphorylation, demonstrating the effects of multiple immunomodulatory soluble factors secreted by MSCs on this signaling molecule, including IDO [47].

Importantly, within this study we demonstrate that MSC secretion of sPD-L1 and L2 both have direct effects on T cell behavior and effector function, but that these effects are differential. It has been previously demonstrated that PD-L1 and PD-L2 directly compete for the PD-1 receptor, however, the nature of the binding interaction is unique, with PD-L1 changing its conformation on binding to PD-1 [25]. Here, these interactions are simplified in this pure co-culture system to delineate direct effects, but within the in vivo context, where PD-L2 has been shown to have direct activating effects on dendritic cells enhancing immune responses [48], we hypothesize that MSCs could utilize their secretion of both of these soluble ligands and their relative frequency to orchestrate adaptive and innate responses.

Combining the knowledge gleaned from this study with the literature, we propose a model (Fig. 6) by which CD3/CD28 costimulation leads to an increased activation of the protein kinase casein kinase 2 (CK2). CK2 leads to phosphorylation of phosphatase and tensin homolog (PTEN) in the C-terminal region, inhibiting its activity. This allows sustained phosphorylation of AKT via PI3K pathway [49]. Phosphorylation of AKT leads to a decrease in FOXO3, ultimately resulting in increased activation, proliferation and effector cytokine production. We demonstrate within this study that MSC derived sPD-1 ligands can directly inhibit this pathway, with sPD-L1 leading to a decrease in AKT phosphorylation at T308 and increased levels of FOXO3. These pathway interruptions lead to a decrease in proliferation, anergy, cell death (via sPD-L1 binding) and a decreased production of IL-2, modulated by both ligands. Decreased CD25 expression in combination with a dampened secretion of IL-2 additionally blocks the auto- and paracrine positive feedback loop on the T cell activation status. As exogenous IL-2 supplementation did not affect CD25 expression, even after MSC removal, we suggest that these effects are separate actions by the MSCs and not a knock-on effect of one another.

In summary, this study reports, for the first time, the secretion and function of sPD-L1 ligands by MSCs, in addition to reporting the first known biological function of sPD-L2. We demonstrate that both PD-L1 and PD-L2 are secreted by MSCs and that this is significantly upregulated in response to pro-inflammatory cytokines. These soluble ligands are secreted at levels sufficiently high enough to dampen the AKT pathway, thereby suppressing the activation status and effector function of T cells, in addition to inducing an irreversible hyporesponsive state.

Acknowledgments
This study was supported by grants from Swedish Cancer Society (11 0315), Children’s Cancer Foundation (PRO111/034), Swedish Medical Research Council (K2011-??X-20742-04-6), VINNOVA (2010-00501), Stockholm County Council (ALF) (20110152), Cancer Society in Stockholm, Swedish Society of Medicine, Tobias Foundation and Karolinska Institutet.

Author Contributions
L.C.D.: Conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing; N.H.: Conception and design, collection of data, data analysis and interpretation, final approval of manuscript; N.K.: Collection of data, data analysis and interpretation, final approval of manuscript; K.L.B.: Conception and design, financial support, provision of study material, final approval of manuscript.

Disclosure of Potential Conflicts of Interest
The authors indicate no potential conflicts of interest.

References
1. Rasmusson I, Ringden O, Sundberg B et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76:1208–1213.
2. Gothenstrom C, Ringden O, Westgren M et al. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant 2003;32:265–272.
3. Roemeling-van Rijn M, Khairoun M, Korevaar SS et al. Human bone marrow- and adipose tissue-derived mesenchymal stromal cells are immunosuppressive and in a humanized allograft rejection model. J Stem Cell Res Ther 2013;Suppl 6(1):20780.
4. Melief SM, Geutskens SB, Fibbe WE et al. Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. Haematologica 2013;98:888–895.
5. Carlsson PO, Schwarz E, Korsgren O et al. Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes 2015;64:587–592.
6. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371:1579–1586.
7. Oh KW, Moon C, Kim HY et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl Med 2015;4:590–597.
8. Melief SM, Schrama E, Brugman MH et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 2013;31:1980–1991.
9. Mougiakakos D, Jitschin R, Johansson CC et al. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011;117:4826–4835.
10. Liu Y, Wang L, Kikuiri T et al. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Nat Med 2011;17:1594–1601.
11. Chen H, Min XH, Wang QY et al. Pre-activation of mesenchymal stem cells with TNF-alpha, IL-1beta and nitric oxide enhances its paracrine effects on radiation-induced intestinal injury. Sci Rep 2015;5:8718.
12. Appleman LJ, van Puijenbroek AA, Shu KM et al. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle
progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J Immunol 2002;168:2729–2736.

13 Giancchelli E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PDL-1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev 2013;12:1091–1100.

14 Parry RV, Chemnitz JM, Frauwirth KA et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005;25:9543–9553.

15 Francisco LM, Salinas VH, Brown KE et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009;206:3015–3029.

16 Bennett F, Luxenberg D, Ling V et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol 2003;170:711–718.

17 Salama AD, Chitnis T, Imtola J et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003;198:10:1563–1572.

18 Nishimura H, Minato N, Nakano T et al. Immunological studies on PD-1 deficient mice: Implication of PD-1 as a negative regulator for B cell responses. Int Immunol 1998;10:1563–1572.

19 Fujiwara H, Maeda Y, Kobayashi K et al. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease. J Immunol 2014;193:2565–2573.

20 Won TJ, Jung YJ, Kwon SJ et al. Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes. Arch Pharm Res 2010;33:1825–1833.

21 Chinnadurai R, Copland IB, Patel SR et al. IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells. J Immunol 2014;192:1451–1501.

22 Yamazaki T, Akiha H, Iwai H et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002;169:5538–5545.

23 Kadi N, Korpos E, Gupta S et al. CD4(+) type II NKT cells mediate ICD and programmed death-1-dependent regulation of type 1 diabetes. J Immunol 2012;188:3138–3149.

24 Kronsteiner B, Wollbank S, Peterbauer A et al. Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells. Stem Cells Dev 2011;20:2115–2126.

25 Ghiozzo M, Gaubieri L, Serriari N et al. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol 2010;22:651–660.

26 Dezutser-Dambuyant C, Durand I, Alberti L et al. A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. Oncomimunology 2016;5:e1091146.

27 He KH, Liu Y, Xu LH et al. Cloning and identification of two novel splice variants of human PD-L2. Acta Biochim Biophys Sin (Shanghai) 2004;36:284–289.

28 Angello A, Tasso R, Negrini SM et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005;35:1482–1490.

29 Le Blanc K, Tamnik L, Sundberg B et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57:11–15.

30 Moll G, Rasmussen-Duprez I, von Bahr L et al. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells Dev 2012;21:1565–1574.

31 Le Blanc K, Samuelsson H, Gustafsson B et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007;21:1733–1738.

32 Velu V, Kannangat S, Ibegbu C et al. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol 2007;81:5819–5828.

33 Kwon MS, Noh MY, Oh KW et al. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients. J Neurochem 2014;131:206–218.

34 Zafrañskaya M, Nizheharodava D, Yurkevich M et al. PGE2 contributes to inflammation of the central nervous system in ALS patients. J Neurochem 2007;105:2821–2827.

35 Chikuma S, Terawaki S, Hayashi T et al. Mesenchymal stem cells decrease the incidence of type 1 diabetes. J Immunol 2007;177:91–100.

36 Chikuma S, Terawaki S, Hayashi T et al. PD-1 mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol 2009;182:6682–6689.

37 Stagg J, Pommey S, Eliopoulos N et al. Interferon-gamma-stimulated marrow stromal cells: A new type of nonhematopoietic antigen-presenting cell. Blood 2006;107:2570–2577.

38 Luz-Crawford P, Noel D, Fernandez X et al. Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One 2012;7:e45272.

39 English K, Barry FP, Field-Corbett CP et al. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007;110:91–100.

40 Augello A, Tasso R, Negrini SM et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005;35:1482–1490.

41 Chikuma S, Terawaki S, Hayashi T et al. Mesenchymal stem cells decrease the incidence of type 1 diabetes. J Immunol 2009;182:6682–6689.

42 Bishop KD, Harris JE, Mordes JP et al. Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+) T lymphocytes via an interleukin-2-dependent mechanism. Cell Immunol 2009;256:86–91.

43 Glennie S, Skea R, Mason PE et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005;105:2821–2827.

44 Pages F, Ragueneau M, Rottapel R et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 1994;369:327–329.

45 Brunet A, Bonni A, Zigmond MJ et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857–868.

46 Lin L, Hron JD, Peng SL. Regulation of NF-kappaB, Ah activation, and autoinflammation by the Forkhead transcription factor Foxo3a. Immunity 2004;21:203–213.

47 Metz R, Rust S, Duhaudaway JB et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 2012;1:1460–1468.

48 Shin T, Yoshimura K, Shin T et al. In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med 2005;201:1531–1541.

49 Patsoukis N, Li L, Sari D et al. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol Cell Biol 2013;33:3091–3098.